CD86 and cancer: Furthermore, co-culturing immature dendritic cells with dying cancer cells targeted by EGFR and TF NIR-PIT agents mediated enhanced dendritic cell maturation, as indicated by increased expression of CD80, CD86, CD40, and HLADR.